RT Journal Article SR Electronic T1 Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and Inhibition JF Drug Metabolism and Disposition JO Drug Metab Dispos FD American Society for Pharmacology and Experimental Therapeutics SP 439 OP 446 DO 10.1124/dmd.31.4.439 VO 31 IS 4 A1 Jasminder Sahi A1 Christopher B. Black A1 Geraldine A. Hamilton A1 Xianxian Zheng A1 Summer Jolley A1 Kelly A. Rose A1 Darryl Gilbert A1 Edward L. LeCluyse A1 Michael W. Sinz YR 2003 UL http://dmd.aspetjournals.org/content/31/4/439.abstract AB Rosiglitazone and pioglitazone are thiazolidinediones used for treatment of noninsulin-dependent diabetes mellitus. These compounds, along with troglitazone, were evaluated for the ability to induce cytochrome P450 enzymes (P450) in primary human hepatocyte cultures and to inhibit P450 in human microsomes. In induction studies, all three thiazolidinediones caused a dose-dependent increase in CYP3A4 activity and immunoreactive protein. While troglitazone was the most potent, rosiglitazone and pioglitazone generally exceeded troglitazone in absolute CYP3A4 activity achieved at concentrations ≥10 μM. A comparable concentration-dependent increase in CYP2B6 immunoreactive protein was observed with all three thiazolidinediones. Microarray analysis revealed rifampin > troglitazone > pioglitazone > rosiglitazone in terms of CYP3A4 mRNA induction potential with 10 μM compound. Inhibition studies conducted for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP2A6, and CYP2E1 showed troglitazone to be the most nonselective and potent inhibitor followed by rosiglitazone and pioglitazone. In vitro, the thiazolidinediones were strong inhibitors of CYP2C8, withKi values between 1.7 and 5.6 μM, and of CYP3A4, with Ki values between 1.6 and 11.8 μM. Troglitazone, in addition, inhibited CYP2C9 (Ki 0.6 μM). Although the inhibitory effects of the thiazolidinediones have not been demonstrated clinically, our results suggest there is potential for interactions with CYP2C8 substrates. This is the first report of in vitro induction of P450 enzymes by rosiglitazone and pioglitazone. While only the induction of CYP3A4 by troglitazone has been demonstrated in vivo, these results suggest that other thiazolidinediones may have the potential to cause clinically significant drug interactions at sufficiently high doses. The American Society for Pharmacology and Experimental Therapeutics